MX2022011596A - Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. - Google Patents

Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.

Info

Publication number
MX2022011596A
MX2022011596A MX2022011596A MX2022011596A MX2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A MX 2022011596 A MX2022011596 A MX 2022011596A
Authority
MX
Mexico
Prior art keywords
coronaviridae infection
assessing
treating
compounds
preventing
Prior art date
Application number
MX2022011596A
Other languages
English (en)
Inventor
Hartmut Ehrlich
Didier Scherrer
Julien Santo
Jamal Tazi
Philippe Pouletty
Original Assignee
Abivax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20305299.8A external-priority patent/EP3881844A1/en
Priority claimed from EP20305327.7A external-priority patent/EP3884946A1/en
Application filed by Abivax filed Critical Abivax
Publication of MX2022011596A publication Critical patent/MX2022011596A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

La presente invención se refiere al tratamiento o prevención de una infección por Coronaviridae, y condiciones relacionadas a la misma; en particular una infección por Coronaviridae en humanos. En particular, la invención se refiere a compuestos, composiciones farmacéuticas y medicamentos para tratar y/o prevenir una infección por Coronaviridae y/o sus consecuencias a largo plazo. La invención se refiere además a usos y métodos para evaluar una infección por Coronaviridae o la eficacia de un tratamiento de tales infecciones.
MX2022011596A 2020-03-20 2021-03-19 Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae. MX2022011596A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20305299.8A EP3881844A1 (en) 2020-03-20 2020-03-20 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305327.7A EP3884946A1 (en) 2020-03-25 2020-03-25 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP20305482 2020-05-12
EP20306483 2020-12-03
PCT/EP2021/057123 WO2021186053A1 (en) 2020-03-20 2021-03-19 Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection

Publications (1)

Publication Number Publication Date
MX2022011596A true MX2022011596A (es) 2022-10-18

Family

ID=74884979

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011596A MX2022011596A (es) 2020-03-20 2021-03-19 Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.

Country Status (11)

Country Link
US (1) US20230142547A1 (es)
EP (1) EP4121053A1 (es)
JP (1) JP2023521564A (es)
KR (1) KR20220152292A (es)
CN (1) CN115605205A (es)
AU (1) AU2021238792A1 (es)
BR (1) BR112022018793A2 (es)
CA (1) CA3172179A1 (es)
IL (1) IL296522A (es)
MX (1) MX2022011596A (es)
WO (1) WO2021186053A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1691800A4 (en) 2003-11-21 2009-03-18 Univ Newcastle Res Ass METHODS AND AGENTS FOR INHIBITING ENDOCYTOSIS DEPENDENT ON DYNAMINE
TR201910781T4 (tr) 2009-06-12 2019-08-21 Abivax Kanser tedavisi için yararlı bileşikler.
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
EP3058940A1 (en) * 2015-02-23 2016-08-24 Abivax Quinoline derivatives for use in the treatment or prevention of viral infection
EP3059236A1 (en) * 2015-02-23 2016-08-24 Abivax A new quinoline derivative for use in the treatment and prevention of viral infections
EP3594206A1 (en) 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection

Also Published As

Publication number Publication date
IL296522A (en) 2022-11-01
AU2021238792A1 (en) 2022-10-13
US20230142547A1 (en) 2023-05-11
CA3172179A1 (en) 2021-09-23
BR112022018793A2 (pt) 2022-11-29
KR20220152292A (ko) 2022-11-15
JP2023521564A (ja) 2023-05-25
WO2021186053A1 (en) 2021-09-23
CN115605205A (zh) 2023-01-13
EP4121053A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
ZA202109010B (en) Compounds and methods for the treatment of covid-19
ATE555810T1 (de) Mittel zur behandlung oder prävention von verdauungsgeschwüren
NO20076675L (no) Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
MX2022015601A (es) Compuesto para el tratamiento de infecciones coronavirales.
SG11201908234WA (en) Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer
PH12019500242A1 (en) 9-aminomethyl minocycline compounds and uses thereof
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
CL2022000214A1 (es) Inhibidores de enzimas
MX2022011596A (es) Compuestos para tratar o prevenir una infeccion por coronaviridae y metodos y usos para evaluar la aparicion de una infeccion por coronaviridae.
MX2021009219A (es) Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria.
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2017012539A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
WO2019155360A3 (en) Pharmaceutical composition for treating bacterial and viral infections
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
BR112022024999A2 (pt) Inibidor tlr7 em combinação com prednisolona ou hidroxicloroquina para o tratamento do lúpus eritematoso cutâneo
TR202106518A2 (tr) KORONAVİRÜS (SARS-COV-2 veya COVID-19) KAYNAKLI VİRAL HASTALIKLARIN PROFİLAKSİSİ VE TEDAVİSİ İÇİN BİR FARMASÖTİK ÜRÜN
MX2023003087A (es) Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.
CR20220453A (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen
PL419082A1 (pl) Ksantohumol do zastosowania w leczeniu lub zapobieganiu i profilaktyce chorób hemoroidalnych oraz kompozycja zawierająca ksantohumol